PRCM
ANIP icon

Pine River Capital Management’s ANI Pharmaceuticals ANIP Stock Holding History

Pine River Capital Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-50,400
Closed -$3.06M – 155
2016
Q4 		$3.06M Hold
50,400
– – 0.11% 102
2016
Q3 		$3.34M Buy
+50,400
New +$3.15M 0.06% 136

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Pine River Capital Management's ANIP Position: Q1 2017 in Review

Pine River Capital Management sold out of ANI Pharmaceuticals (ANIP) in Q1 2017, closing a stake of 50,400 shares — an estimated $3.06M sold.

Pine River Capital Management first reported a position in ANIP in Q3 2016 and held it in 2 quarters. The position peaked at $3.34M in Q3 2016. 158 funds tracked by Wall St. Rank hold ANIP as of Q1 2017.

  • Pine River Capital Management reported no remaining ANI Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Pine River Capital Management sold 50,400 ANI Pharmaceuticals shares in Q1 2017, an estimated $3.06M.
  • Pine River Capital Management first reported a position in ANI Pharmaceuticals in Q3 2016 and held it in 2 quarters.
  • Pine River Capital Management's ANI Pharmaceuticals position peaked at $3.34M in Q3 2016.
  • 158 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2017.

Based on Pine River Capital Management's 13F filing for Q1 2017, filed 15 May 2017.